RU2013151166A - Способ модуляции активности цитокинов - Google Patents
Способ модуляции активности цитокинов Download PDFInfo
- Publication number
- RU2013151166A RU2013151166A RU2013151166/15A RU2013151166A RU2013151166A RU 2013151166 A RU2013151166 A RU 2013151166A RU 2013151166/15 A RU2013151166/15 A RU 2013151166/15A RU 2013151166 A RU2013151166 A RU 2013151166A RU 2013151166 A RU2013151166 A RU 2013151166A
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- hydrogen
- substituted
- oxo
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title claims 6
- 108090000695 Cytokines Proteins 0.000 title claims 6
- 230000000694 effects Effects 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 42
- 125000000217 alkyl group Chemical group 0.000 claims abstract 40
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 30
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 27
- 239000001257 hydrogen Substances 0.000 claims abstract 27
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 21
- 229910052736 halogen Inorganic materials 0.000 claims abstract 20
- 150000002367 halogens Chemical class 0.000 claims abstract 20
- 150000002431 hydrogen Chemical class 0.000 claims abstract 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 18
- 125000003118 aryl group Chemical group 0.000 claims abstract 17
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 14
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 13
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims abstract 12
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 12
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract 10
- 150000001721 carbon Chemical group 0.000 claims abstract 10
- 125000004470 heterocyclooxy group Chemical group 0.000 claims abstract 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 9
- 239000001301 oxygen Substances 0.000 claims abstract 9
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract 6
- 229930195729 fatty acid Natural products 0.000 claims abstract 6
- 239000000194 fatty acid Substances 0.000 claims abstract 6
- 150000004665 fatty acids Chemical class 0.000 claims abstract 6
- 229910052717 sulfur Chemical group 0.000 claims abstract 6
- 239000011593 sulfur Chemical group 0.000 claims abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 230000002519 immonomodulatory effect Effects 0.000 claims 5
- 206010030216 Oesophagitis Diseases 0.000 claims 4
- 208000006881 esophagitis Diseases 0.000 claims 4
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- -1 1,1-difluoropentyl Chemical group 0.000 claims 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 claims 1
- CTQWVWWSERVGET-HZPDHXFCSA-N 7-[(1r,2r)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1CCC(=O)[C@@H]1CCCCCCC(O)=O CTQWVWWSERVGET-HZPDHXFCSA-N 0.000 claims 1
- SDDSJMXGJNWMJY-BRHAQHMBSA-N 7-[(2r,4ar,5r,7ar)-2-[(3s)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid Chemical compound O1[C@](C(F)(F)C[C@@H](C)CC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 SDDSJMXGJNWMJY-BRHAQHMBSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 0 **C(C(B*O*)C(C1CN)N)C1I Chemical compound **C(C(B*O*)C(C1CN)N)C1I 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161476992P | 2011-04-19 | 2011-04-19 | |
| US61/476,992 | 2011-04-19 | ||
| US201161489516P | 2011-05-24 | 2011-05-24 | |
| US61/489,516 | 2011-05-24 | ||
| US201161537305P | 2011-09-21 | 2011-09-21 | |
| US61/537,305 | 2011-09-21 | ||
| US201161548458P | 2011-10-18 | 2011-10-18 | |
| US61/548,458 | 2011-10-18 | ||
| PCT/JP2012/061004 WO2012144649A1 (en) | 2011-04-19 | 2012-04-18 | Method for modulating cytokine activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013151166A true RU2013151166A (ru) | 2015-05-27 |
Family
ID=47021806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013151166/15A RU2013151166A (ru) | 2011-04-19 | 2012-04-18 | Способ модуляции активности цитокинов |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120270945A1 (enExample) |
| EP (1) | EP2699244A4 (enExample) |
| JP (1) | JP2014511825A (enExample) |
| KR (1) | KR20140043075A (enExample) |
| CN (2) | CN103781482A (enExample) |
| AU (2) | AU2012246999A1 (enExample) |
| BR (1) | BR112013026644A2 (enExample) |
| CA (1) | CA2831869A1 (enExample) |
| IL (1) | IL228700A0 (enExample) |
| MX (1) | MX2013012251A (enExample) |
| RU (1) | RU2013151166A (enExample) |
| TW (1) | TW201247615A (enExample) |
| WO (1) | WO2012144649A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0708362A2 (pt) * | 2006-02-28 | 2011-05-24 | Sucampo Ag | método e composição para o tratamento de doença pulmonar obstrutiva crÈnica |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| US20150099802A1 (en) * | 2013-10-03 | 2015-04-09 | Sucampo Ag | Selective tumor treatment |
| JP6090723B2 (ja) * | 2013-10-04 | 2017-03-08 | 国立大学法人東北大学 | 腎機能障害の予防又は改善剤 |
| US20160120840A1 (en) * | 2014-10-30 | 2016-05-05 | Sucampo Ag | Method and composition for treating nonerosive reflux disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166174A (en) * | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| ATE148344T1 (de) * | 1990-04-27 | 1997-02-15 | R Tech Ueno Ltd | Verwendung von 15-dehydroxy-16-oxoprostaglandin bei der behandlung von allergischen erkrankungen |
| JPH0770054A (ja) * | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
| CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| JPH1029942A (ja) * | 1996-04-02 | 1998-02-03 | Yoichi Ichikawa | 慢性関節リウマチ治療剤 |
| NZ556710A (en) * | 2005-01-27 | 2010-08-27 | Sucampo Ag | Method and composition for treating central nervous system disorders |
| NZ561414A (en) * | 2005-03-04 | 2010-10-29 | Sucampo Ag | Method and composition for treating peripheral vascular diseases |
| CN101180096B (zh) * | 2005-03-21 | 2015-04-22 | 苏坎波公司 | 用于治疗粘膜疾病的方法和组合物 |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| EP1871380B1 (en) * | 2005-04-12 | 2011-10-19 | Sucampo AG | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders |
| BRPI0708362A2 (pt) * | 2006-02-28 | 2011-05-24 | Sucampo Ag | método e composição para o tratamento de doença pulmonar obstrutiva crÈnica |
| EP2147672A4 (en) * | 2007-05-08 | 2011-11-02 | Nat University Corp Hamamatsu University School Of Medicine | CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST |
| WO2009133863A1 (ja) * | 2008-04-28 | 2009-11-05 | 国立大学法人浜松医科大学 | Ｅｐ１アゴニストを含有してなる免疫増強剤 |
| JP2011032262A (ja) * | 2009-06-30 | 2011-02-17 | Sucampo Ag | Ｎｓａｉｄの長期使用のための医薬組成物 |
| NZ608823A (en) * | 2010-10-15 | 2014-11-28 | Scinopharm Kunshan Biochemical Technology Co Ltd | Processes for preparation of lubiprostone |
-
2012
- 2012-04-18 KR KR1020137030512A patent/KR20140043075A/ko not_active Ceased
- 2012-04-18 RU RU2013151166/15A patent/RU2013151166A/ru not_active Application Discontinuation
- 2012-04-18 CN CN201280030108.4A patent/CN103781482A/zh active Pending
- 2012-04-18 US US13/450,071 patent/US20120270945A1/en not_active Abandoned
- 2012-04-18 CN CN201710153095.4A patent/CN107028952A/zh active Pending
- 2012-04-18 WO PCT/JP2012/061004 patent/WO2012144649A1/en not_active Ceased
- 2012-04-18 CA CA2831869A patent/CA2831869A1/en not_active Abandoned
- 2012-04-18 AU AU2012246999A patent/AU2012246999A1/en not_active Abandoned
- 2012-04-18 BR BR112013026644A patent/BR112013026644A2/pt active Search and Examination
- 2012-04-18 MX MX2013012251A patent/MX2013012251A/es unknown
- 2012-04-18 EP EP12774360.7A patent/EP2699244A4/en not_active Withdrawn
- 2012-04-18 JP JP2013548650A patent/JP2014511825A/ja not_active Ceased
- 2012-04-19 TW TW101113907A patent/TW201247615A/zh unknown
-
2013
- 2013-10-03 IL IL228700A patent/IL228700A0/en unknown
-
2017
- 2017-05-16 AU AU2017203276A patent/AU2017203276A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2699244A1 (en) | 2014-02-26 |
| AU2017203276A1 (en) | 2017-06-08 |
| CN107028952A (zh) | 2017-08-11 |
| IL228700A0 (en) | 2013-12-31 |
| JP2014511825A (ja) | 2014-05-19 |
| MX2013012251A (es) | 2014-01-20 |
| CN103781482A (zh) | 2014-05-07 |
| BR112013026644A2 (pt) | 2016-12-27 |
| KR20140043075A (ko) | 2014-04-08 |
| EP2699244A4 (en) | 2014-10-22 |
| WO2012144649A1 (en) | 2012-10-26 |
| US20120270945A1 (en) | 2012-10-25 |
| NZ616027A (en) | 2015-09-25 |
| AU2012246999A1 (en) | 2013-10-17 |
| TW201247615A (en) | 2012-12-01 |
| CA2831869A1 (en) | 2012-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010138603A (ru) | Композиция для модуляции роста стволовых клеток простагландинами | |
| RU2013151166A (ru) | Способ модуляции активности цитокинов | |
| CA2600331A1 (en) | Use of 11-deoxy-prostaglandin for treating peripheral vascular diseases | |
| JP2008531468A5 (enExample) | ||
| AR064788A1 (es) | Compuestos de ciclohexenona de la antrodia comphorata y usos de los mismos | |
| WO2013121449A8 (en) | Compositions and methods for the modulation of specific amidases for n-acylethanolamines for use in the therapy of inflammatory diseases | |
| MX2010009959A (es) | Compuestos y metodo para reducir el acido urico. | |
| RU2012119778A (ru) | Водная композиция | |
| RU2018113296A (ru) | Фармацевтическая композиция, содержащая 11-дезокси-простагландиновое соединение и способ стабилизации этого соединения | |
| JP2014511825A5 (enExample) | ||
| RU2012150501A (ru) | Противораковые стероидные лактоны, ненасыщенные в положении 7(8) | |
| JP2008528440A5 (enExample) | ||
| KR20140072102A (ko) | 점막 장애 치료 방법 및 조성물 | |
| RU2007132081A (ru) | Способ и композиция для лечения заболеваний центральной нервной системы | |
| RU2014108423A (ru) | Способ лечения шизофрении | |
| RU2011146128A (ru) | Способ и композиция для лечения дегенерации желтого пятна | |
| RU2011153196A (ru) | Фармацевтическая композиция, содержащая производные простагландинов, для применения в модулировании опосредованных клаудином функций и лечении дерматологических нарушений | |
| JP2014510022A5 (enExample) | ||
| JP2004519412A5 (enExample) | ||
| CA2404767A1 (en) | Bile secretion promoting composition containing a 15-keto prostaglandin | |
| US20150099802A1 (en) | Selective tumor treatment | |
| JP2014527048A5 (enExample) | ||
| JP2016528165A5 (enExample) | ||
| JP2004529177A5 (enExample) | ||
| RU2012114771A (ru) | Фармацевтическая комбинация для лечения опухоли |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171121 |